A European working group has provided a new set of recommendations for the use of cerebrospinal fluid (CSF) biomarkers in the diagnostic evaluation of Alzheimer disease and mild cognitive impairment. These recommendations represent an important step towards the implementation of CSF biomarker tests in the clinic, but several challenges remain.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Alzheimer disease pathology and the cerebrospinal fluid proteome
Alzheimer's Research & Therapy Open Access 18 July 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263–269 (2011).
Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 11, 614–629 (2014).
Simonsen, A. H. et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2016.09.008 (2016).
Herukka, S.-K. et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of MCI. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2016.09.009 (2016).
Carrillo, M. C. et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 9, 137–140 (2013).
Bittner, T. et al. Technical performance of a novel fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 12, 517–526 (2016).
Panee, J. et al. Round robin test on qualification of amyloid-B 1–42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement. 12, 55–59 (2016).
Struyfs, H. et al. Diagnostic accuracy of cerebrospinal fluid amyloid-β Isoforms for early and differential dementia diagnosis. J. Alzheimers Dis. 45, 813–822 (2015).
Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240–1249 (2015).
Jack, C. R. et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
Acknowledgements
The authors acknowledge grant support from the NIH National Institute on Aging (grant AGO5131 to D.R.G. and grant U01 AG024904 to L.M.S.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Galasko, D., Shaw, L. CSF biomarkers for Alzheimer disease — approaching consensus. Nat Rev Neurol 13, 131–132 (2017). https://doi.org/10.1038/nrneurol.2017.11
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.11
This article is cited by
-
Olfactory and other sensory impairments in Alzheimer disease
Nature Reviews Neurology (2019)
-
Altered effective connectivity anchored in the posterior cingulate cortex and the medial prefrontal cortex in cognitively intact elderly APOE ε4 carriers: a preliminary study
Brain Imaging and Behavior (2019)
-
Alzheimer disease pathology and the cerebrospinal fluid proteome
Alzheimer's Research & Therapy (2018)
